← back to search

Rinee Mukherjee

Merck & Co., Inc., Rahway, NJ, USA (United States) · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, and Lung Cancer Research Studies.
h-index
2
citations
318
works
2
NIH funding
—
primary concept
Lung cancer
email
✉ Find email ↗

Recent publications

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Journal of Clinical Oncology 2022cited by 302position: middledoi
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
Regular and Young Investigator Award Abstracts 2021cited by 16position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gilberto de Castro · Twitter (United States)2 papers (2021–2022)Bogusława Karaszewska · State University of Applied Sciences in Konin2 papers (2021–2022)Li Zhang · Shandong Academy of Pharmaceutical Sciences2 papers (2021–2022)Yi‐Long Wu · China Agricultural University2 papers (2021–2022)H.Z. Turna · Istanbul University2 papers (2021–2022)Jianxin Lin · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2021–2022)Fabricio Souza · Daiichi Sankyo (United States)2 papers (2021–2022)Christian Caglevic · Clínica Alemana2 papers (2021–2022)Igor Bondarenko · Dnipro State Medical University2 papers (2021–2022)Iveta Kudaba · Riga Aeronautical Institute2 papers (2021–2022)Byoung Chul Cho · Université Grenoble Alpes2 papers (2021–2022)Tony Mok · South China University of Technology2 papers (2021–2022)Gilberto Lopes · Premier Research Group2 papers (2021–2022)Dariusz M. Kowalski · National Institute of Oncology2 papers (2021–2022)Vichien Srimuninnimit · Siriraj Hospital2 papers (2021–2022)К. К. Лактионов · Ministry of Health of the Russian Federation2 papers (2021–2022)— · 1 papers (2021–2021)Kaoru Kubota · Nippon Medical School1 papers (2022–2022)